NCT02025972

Allogeneic Umbilical Cord Blood Therapy in Children With CP

Changes in Cytokines and Functional Outcomes of Allogeneic Cord Blood Therapy in Children With Cerebral Palsy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: MinYoung Kim, M.D. · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

This open-label study aims to analyze cytokines related to clinical outcomes of allogeneic umbilical cord blood therapy for children with cerebral palsy.

Detailed description

Cerebral palsy (CP) is a group of neurodevelopmental conditions with abnormal movement and posture resulted from a non-progressive cerebral disturbance. It is the most common cause of motor disability in childhood. Most therapies are palliative rather than restorative. Umbilical cord blood (UCB) may be used as restorative approach for children with CP. Many experimental animal studies have revealed that UCB is beneficial to improve and repair neurological injuries. Based on animal studies and some clinical trials, UCB is suggested as a potential therapy for children with CP. This study was designed to find cytokines relevant to UCB therapy.

Conditions

• Cerebral Palsy

Interventions

Type	Name	Description
PROCEDURE	Allogeneic umbilical cord blood therapy

Timeline

• Start date: 2013-12-01
• Primary completion: 2015-11-15
• Completion: 2015-11-15
• First posted: 2014-01-01
• Last updated: 2017-10-12

Locations

1 site across 1 country: South Korea